Voyager Historical Income Statement

VYGR Stock

USD 5.78 0.11 1.94%

Historical analysis of Voyager Therapeutics income statement accounts such as Depreciation And Amortization of 3.5 M, Selling General Administrative of 26 M, Gross Profit of 257.8 M or Other Operating Expenses of 92.6 M can show how well Voyager Therapeutics performed in making a profits. Evaluating Voyager Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Voyager Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Voyager Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Voyager Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyager Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide.

About Voyager Income Statement Analysis

Voyager Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Voyager Therapeutics shareholders. The income statement also shows Voyager investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Voyager Therapeutics Income Statement Chart

At this time, Voyager Therapeutics' Income Tax Expense is relatively stable compared to the past year. As of 11/28/2024, Interest Expense is likely to grow to about 2.2 M, while Selling General Administrative is likely to drop slightly above 26 M.

Selling General Administrative Other Operating Expenses Research Development Cost Of Revenue Net Income From Continuing Ops

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Voyager Therapeutics. It is also known as Voyager Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Voyager Therapeutics income statement and represents the costs associated with goods and services Voyager Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Voyager Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Voyager Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyager Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide.At this time, Voyager Therapeutics' Income Tax Expense is relatively stable compared to the past year. As of 11/28/2024, Interest Expense is likely to grow to about 2.2 M, while Selling General Administrative is likely to drop slightly above 26 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	111.0M	91.7M	128.0M	92.2M
Cost Of Revenue	73.8M	6.2M	4.4M	4.2M

Total Operating Expenses Cost Of Revenue

Voyager Therapeutics income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Interest Expense	Total Revenue	Net Income From Continuing Ops	Interest Income	Tax Provision	Net Interest Income	Non Operating Income Net Other	Reconciled Depreciation
Depreciation And Amortization		-0.23	-0.08	-0.3	0.15	0.15	-0.31	0.19	-0.38	-0.32	0.15	0.1	0.15	0.04	-0.03	-0.07	0.11	-0.29	0.01	-0.1	0.08	0.17
Selling General Administrative	-0.23		0.55	0.97	0.03	0.03	0.94	0.02	0.62	0.97	0.09	0.69	0.09	-0.35	0.39	0.59	0.13	0.47	0.24	0.46	0.61	0.75
Gross Profit	-0.08	0.55		0.58	0.79	0.79	0.58	0.78	-0.03	0.58	0.82	0.8	0.82	0.3	0.78	0.95	0.84	0.08	0.92	0.95	0.43	0.54
Other Operating Expenses	-0.3	0.97	0.58		0.08	0.08	1.0	0.07	0.71	1.0	0.14	0.72	0.15	-0.35	0.33	0.65	0.18	0.58	0.25	0.49	0.65	0.65
Operating Income	0.15	0.03	0.79	0.08		1.0	0.1	1.0	-0.41	0.07	1.0	0.54	1.0	0.59	0.61	0.81	0.99	-0.33	0.9	0.75	0.38	0.23
Ebit	0.15	0.03	0.79	0.08	1.0		0.1	1.0	-0.41	0.08	1.0	0.54	1.0	0.59	0.61	0.81	0.99	-0.33	0.9	0.75	0.38	0.23
Research Development	-0.31	0.94	0.58	1.0	0.1	0.1		0.08	0.74	0.99	0.15	0.72	0.16	-0.35	0.3	0.66	0.19	0.6	0.25	0.49	0.66	0.6
Ebitda	0.19	0.02	0.78	0.07	1.0	1.0	0.08		-0.42	0.06	1.0	0.54	1.0	0.59	0.61	0.8	0.99	-0.34	0.89	0.74	0.38	0.23
Cost Of Revenue	-0.38	0.62	-0.03	0.71	-0.41	-0.41	0.74	-0.42		0.71	-0.37	0.25	-0.36	-0.71	-0.37	0.1	-0.34	0.75	-0.37	-0.09	0.42	0.11
Total Operating Expenses	-0.32	0.97	0.58	1.0	0.07	0.08	0.99	0.06	0.71		0.13	0.72	0.14	-0.35	0.34	0.64	0.17	0.57	0.25	0.49	0.65	0.65
Income Before Tax	0.15	0.09	0.82	0.14	1.0	1.0	0.15	1.0	-0.37	0.13		0.6	1.0	0.58	0.63	0.84	1.0	-0.29	0.91	0.78	0.41	0.27
Total Other Income Expense Net	0.1	0.69	0.8	0.72	0.54	0.54	0.72	0.54	0.25	0.72	0.6		0.61	0.11	0.56	0.85	0.62	0.29	0.62	0.75	0.63	0.61
Net Income	0.15	0.09	0.82	0.15	1.0	1.0	0.16	1.0	-0.36	0.14	1.0	0.61		0.56	0.63	0.84	1.0	-0.29	0.91	0.78	0.42	0.28
Income Tax Expense	0.04	-0.35	0.3	-0.35	0.59	0.59	-0.35	0.59	-0.71	-0.35	0.58	0.11	0.56		0.47	0.25	0.56	-0.34	0.52	0.45	-0.22	-0.18
Interest Expense	-0.03	0.39	0.78	0.33	0.61	0.61	0.3	0.61	-0.37	0.34	0.63	0.56	0.63	0.47		0.68	0.65	-0.28	0.79	0.7	0.27	0.66
Total Revenue	-0.07	0.59	0.95	0.65	0.81	0.81	0.66	0.8	0.1	0.64	0.84	0.85	0.84	0.25	0.68		0.86	0.09	0.84	0.88	0.65	0.56
Net Income From Continuing Ops	0.11	0.13	0.84	0.18	0.99	0.99	0.19	0.99	-0.34	0.17	1.0	0.62	1.0	0.56	0.65	0.86		-0.27	0.92	0.8	0.44	0.29
Interest Income	-0.29	0.47	0.08	0.58	-0.33	-0.33	0.6	-0.34	0.75	0.57	-0.29	0.29	-0.29	-0.34	-0.28	0.09	-0.27		-0.24	0.19	0.04	-0.06
Tax Provision	0.01	0.24	0.92	0.25	0.9	0.9	0.25	0.89	-0.37	0.25	0.91	0.62	0.91	0.52	0.79	0.84	0.92	-0.24		0.9	0.24	0.37
Net Interest Income	-0.1	0.46	0.95	0.49	0.75	0.75	0.49	0.74	-0.09	0.49	0.78	0.75	0.78	0.45	0.7	0.88	0.8	0.19	0.9		0.23	0.36
Non Operating Income Net Other	0.08	0.61	0.43	0.65	0.38	0.38	0.66	0.38	0.42	0.65	0.41	0.63	0.42	-0.22	0.27	0.65	0.44	0.04	0.24	0.23		0.67
Reconciled Depreciation	0.17	0.75	0.54	0.65	0.23	0.23	0.6	0.23	0.11	0.65	0.27	0.61	0.28	-0.18	0.66	0.56	0.29	-0.06	0.37	0.36	0.67

Click cells to compare fundamentals

Voyager Therapeutics Account Relationship Matchups

Voyager Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.8M	3.8M	5.2M	6.2M	4.4M	3.5M
Selling General Administrative	36.3M	35.0M	37.2M	31.0M	35.8M	26.0M
Gross Profit	104.4M	62.4M	37.4M	40.9M	245.6M	257.8M
Other Operating Expenses	156.1M	143.7M	111.0M	91.7M	128.0M	92.6M
Operating Income	(51.7M)	27.4M	(73.6M)	(50.8M)	122.0M	128.1M
Ebit	(51.7M)	27.4M	(73.6M)	(50.8M)	122.0M	128.1M
Research Development	119.7M	108.8M	73.8M	60.8M	92.2M	66.6M
Ebitda	(48.9M)	31.2M	(68.5M)	(44.6M)	126.5M	132.8M
Cost Of Revenue	119.7M	108.8M	73.8M	6.2M	4.4M	4.2M
Total Operating Expenses	156.1M	143.7M	111.0M	91.7M	128.0M	92.2M
Income Before Tax	(43.6M)	36.7M	(71.2M)	(46.4M)	133.7M	140.4M
Total Other Income Expense Net	8.1M	9.4M	2.4M	4.4M	11.7M	12.3M
Net Income	(40.8M)	36.7M	(66.0M)	(46.4M)	132.3M	138.9M
Income Tax Expense	(2.8M)	(1.7M)	(5.2M)	16K	1.4M	1.5M
Total Revenue	104.4M	171.1M	37.4M	40.9M	250.0M	262.5M
Net Income From Continuing Ops	(43.6M)	36.7M	(71.2M)	(46.4M)	132.3M	138.9M
Net Income Applicable To Common Shares	(43.6M)	36.7M	(71.2M)	(46.4M)	(41.8M)	(43.9M)
Interest Income	3.3M	6.5M	1.7M	334K	384.1K	364.9K
Net Interest Income	6.5M	1.7M	(390K)	1.8M	11.7M	12.3M
Non Operating Income Net Other	1.6M	7.7M	2.8M	2.7M	3.1M	2.2M
Reconciled Depreciation	2.8M	3.8M	5.2M	6.2M	4.4M	4.1M

Pair Trading with Voyager Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Voyager Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Voyager Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Voyager Stock

0.64

OPT

Opthea

Pair Corr

Moving against Voyager Stock

0.37

MNOV

MediciNova

Pair Corr

The ability to find closely correlated positions to Voyager Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Voyager Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Voyager Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Voyager Therapeutics to buy it.

The correlation of Voyager Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Voyager Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Voyager Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Voyager Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Voyager Stock Analysis

When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Voyager Historical Income Statement

About Voyager Income Statement Analysis

Voyager Therapeutics Income Statement Chart

Other Operating Expenses

Cost Of Revenue

Voyager Therapeutics income statement Correlations

Voyager Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Voyager Therapeutics income statement Accounts

Pair Trading with Voyager Therapeutics

Moving together with Voyager Stock

Moving against Voyager Stock

Additional Tools for Voyager Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income

Income Tax Expense	- 0.71	Cost Of Revenue
Cost Of Revenue	- 0.42	Ebitda
Cost Of Revenue	- 0.41	Ebit
Cost Of Revenue	- 0.41	Operating Income
Cost Of Revenue	- 0.38	Depreciation And Amortization
Tax Provision	- 0.37	Cost Of Revenue